Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 152, Issue 5, Pages 962-976Publisher
WILEY
DOI: 10.1002/ijc.34319
Keywords
apoptosis; cervical cancer; mitochondrial DNA; PI polyamide; SNP
Categories
Ask authors/readers for more resources
A study found that a compound CCC-h1005 based on triphenylphosphonium has specific cytotoxic effects on cervical cancer cells and cisplatin-resistant cells, and can inhibit tumor growth in a HeLa tumor model without severe adverse effects. This provides a foundation for clinical trials of this class of molecules for treating cervical cancer and other types of cancers.
Cervical cancer remains a major threat to women's health, especially in countries with limited medical resources, and new drugs are needed to improve patient survival and minimize adverse effects. Here, we examine the effects of a triphenylphosphonium (TPP)-conjugated pyrrole-imidazole polyamide (CCC-h1005) targeting the common homoplasmic mitochondrial DNA (mtDNA) cancer risk variant (ATP6 8860A>G) on the survival of cervical cancer cell lines, cisplatin-resistant HeLa cells and patient-derived cervical clear cell carcinoma cells as models of cervical cancer treatment. We found that CCC-h1005 induced death in these cells and suppressed the growth of xenografted HeLa tumors with no severe adverse effects. These results suggest that PIP-TPP designed to target mtDNA cancer risk variants can be used to treat many cervical cancers harboring high copies of the target variant, providing a foundation for clinical trials of this class of molecules for treating cervical cancer and other types of cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available